Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma

Mai, Hai‐Qiang; Chen, Qiuyan; Chen, Dongping; Hu, Chaosu; Yang, Kunyu; Wen, Jiyu; Li, Jingao; Shi, Yingrui; Jin, Feng; Xu, Ruilian; Pan, Jianji; Qu, Shenhong; Li, Ping; Hu, Chunhong; Liu, Yi‐Chun; Jiang, Yi; He, Xia; Wang, Hung‐Ming; Lim, Wan‐Teck; Liao, Wangjun; He, Xiaohui; Chen, Xiaozhong; Wang, Siyang; Yuan, Xianglin; Li, Qi; Lin, Xiaoyan; Jing, Shanghua; Chen, Yanju; Yin, Lu; Hsieh, Ching-Yun; Yang, Muh‐Hwa; Yen, Chia‐Jui; Samol, Jens; Luo, Xianming; Wang, Xiaojun; Tang, Xiongwen; Feng, Hui; Yao, Sheng; Keegan, Patricia; Xu, Rui‐Hua

doi:10.1001/jama.2023.20181

Public

Toripalimab Plus Chemotherapy for Recurrent or Metastatic Nasopharyngeal Carcinoma

Published in JAMA • Nov 28, 2023

Authors:

Hai‐Qiang Mai

Qiuyan Chen

Dongping Chen

Abstract

Importance: There are currently no therapies approved by the US Food and Drug Administration for nasopharyngeal carcinoma (NPC). Gemcitabine-cisplatin is the current standard of care for the first-line treatment of recurrent or metastatic NPC (RM-NPC). Objective: To determine whether toripalimab in ...

Subject

Medicine

Gemcitabine

Internal medicine

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!